Infectious Disease Pathways

HIV testing, CD4/viral load interpretation, and ART initiation

Eron class severity assessment, antibiotic selection, and admission criteria for cellulitis

TB investigation, LTBI testing, and treatment regimens — standard and drug-resistant

Uncomplicated UTI, catheter-associated UTI, and upper UTI management

COVID-19 severity assessment, escalation, and antiviral/steroid treatment

Empirical and organism-directed antibiotic regimens for infective endocarditis

Travel history + targeted workup, malaria first, isolation for VHF risk, notification of NaTHNaC / Public Health.

Thick + thin film + RDT, distinguish severe (artesunate) from uncomplicated (ACT), species-specific therapy, severe complications.

Risk-based screening, distinguish acute / chronic, antiviral therapy, HCC surveillance.

NICE NG95 — erythema migrans = clinical diagnosis; targeted serology for non-EM features; doxycycline first-line.

Recognise CRBSI, paired peripheral + line cultures, line removal threshold, antimicrobial choice by organism.

≥2 UTI in 6 months / ≥3 in 12 months — investigation + non-antibiotic + antibiotic prevention strategies.

BASHH — comprehensive screen for chlamydia, gonorrhoea, syphilis, HIV, hepatitis B/C; partner notification.

Definition (Petersdorf), structured stepwise workup (history, exam, bloods, imaging, biopsy), MDT.

IDSA / IWGDF — severity classification, multidisciplinary foot team, antibiotic + surgical, osteomyelitis recognition.

Clinical features + targeted testing, macrolide / tetracycline / fluoroquinolone, public health (Legionella).

Stage clinically + serologically, benzathine penicillin G, Jarisch-Herxheimer counselling, partner notification, follow-up.